As complexity increases, trial managers are looking to technology to help reduce the administrative burden. Join Marion Mays as she looks at the past, present and future of eTMF development.

Phillip Doyle from Doyle GxP discusses GxP principles for small biotechs. Covering areas such as when in the drug development journey quality and compliance principles should apply, how to apply them, and why GxP guidelines are important for creating an early culture of quality, you won't want to miss this session.

Join Egnyte's Product Experts for a series of live demonstrations of Egnyte's Life Sciences Solutions. Demos include functional tours of: GxP, Quality Document Management, and eTMF.

The estimated value of blockchain technology to the life sciences sector is predicted to be somewhere between $3B and $5.6B by 2025, primarily due to the imperative for secure communication between stakeholders organizing clinical trials. Join the discussion to learn how life science companies are starting to leverage blockchain technology to improve data integrity, security, and accessibility in modern clinical trials.

Decentralized Clinical Trials (DCTs) have increased in popularity during the pandemic. DCTs tout better patient participation, lower dropout rates, and more diverse patient pools. But as the world opens up and traditional clinical trial capacity returns to pre-pandemic levels, will DCTs maintain their popularity? Join industry experts from Bristol Myers Squibb (BMS) and Thread(R) as they discuss the merits and future of DCTs.